Grant T Corbett

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8907660/publications.pdf

Version: 2024-02-01

20 papers

1,328 citations

16 h-index 752256 20 g-index

21 all docs

21 docs citations

times ranked

21

2354 citing authors

#	Article	IF	Citations
1	PrP is a central player in toxicity mediated by soluble aggregates of neurodegeneration-causing proteins. Acta Neuropathologica, 2020, 139, 503-526.	3.9	110
2	Soluble tau aggregates inhibit synaptic long-term depression and amyloid \hat{l}^2 -facilitated LTD in vivo. Neurobiology of Disease, 2019, 127, 582-590.	2.1	25
3	PrP-grafted antibodies bind certain amyloid \hat{l}^2 -protein aggregates, but do not prevent toxicity. Brain Research, 2019, 1710, 125-135.	1.1	14
4	Cellular Prion Protein Mediates the Disruption of Hippocampal Synaptic Plasticity by Soluble Tau <i>In Vivo</i> . Journal of Neuroscience, 2018, 38, 10595-10606.	1.7	66
5	Selective disruption of TLR2-MyD88 interaction inhibits inflammation and attenuates Alzheimer's pathology. Journal of Clinical Investigation, 2018, 128, 4297-4312.	3.9	97
6	Extracellular Forms of Aβ and Tau from iPSC Models of Alzheimer's Disease Disrupt Synaptic Plasticity. Cell Reports, 2018, 23, 1932-1938.	2.9	60
7	Detection of Aggregation-Competent Tau in Neuron-Derived Extracellular Vesicles. International Journal of Molecular Sciences, 2018, 19, 663.	1.8	140
8	Store depletion-induced h-channel plasticity rescues a channelopathy linked to Alzheimer's disease. Neurobiology of Learning and Memory, 2018, 154, 141-157.	1.0	17
9	Cryopreservation Maintains Functionality of Human iPSC Dopamine Neurons and Rescues Parkinsonian Phenotypes InÂVivo. Stem Cell Reports, 2017, 9, 149-161.	2.3	66
10	Human Brain-Derived Al 2 Oligomers Bind to Synapses and Disrupt Synaptic Activity in a Manner That Requires APP. Journal of Neuroscience, 2017, 37, 11947-11966.	1.7	108
11	Intranasal Delivery of NEMO-Binding Domain Peptide Prevents Memory Loss inÂaÂMouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 47, 385-402.	1.2	41
12	HMG-CoA Reductase Inhibitors Bind to PPARÎ \pm to Upregulate Neurotrophin Expression in the Brain and Improve Memory in Mice. Cell Metabolism, 2015, 22, 253-265.	7.2	122
13	Activation of peroxisome proliferator-activated receptor \hat{l}_{\pm} stimulates ADAM10-mediated proteolysis of APP. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 8445-8450.	3.3	116
14	The native form of $\hat{l}\pm\hat{a}\in S$ ynuclein: Monomer, tetramer, or a combination in equilibrium. Movement Disorders, 2015, 30, 1870-1870.	2.2	5
15	Non-Neuronal Cells Exacerbate Â-Amyloid Aggregation in the Aged Brain. Journal of Neuroscience, 2014, 34, 9825-9827.	1.7	1
16	Regulation of Cyclic AMP Response Element Binding and Hippocampal Plasticity-Related Genes by Peroxisome Proliferator-Activated Receptor α. Cell Reports, 2013, 4, 724-737.	2.9	130
17	Altered Spinal MicroRNA-146a and the MicroRNA-183 Cluster Contribute to Osteoarthritic Pain in Knee Joints. Journal of Bone and Mineral Research, 2013, 28, 2512-2522.	3.1	73
18	Sodium Phenylbutyrate Enhances Astrocytic Neurotrophin Synthesis via Protein Kinase C (PKC)-mediated Activation of cAMP-response Element-binding Protein (CREB). Journal of Biological Chemistry, 2013, 288, 8299-8312.	1.6	47

#	Article	IF	CITATIONS
19	Gemfibrozil, a Lipid-Lowering Drug, Upregulates IL-1 Receptor Antagonist in Mouse Cortical Neurons: Implications for Neuronal Self-Defense. Journal of Immunology, 2012, 189, 1002-1013.	0.4	50
20	Gemfibrozil and Fenofibrate, Food and Drug Administration-approved Lipid-lowering Drugs, Up-regulate Tripeptidyl-peptidase 1 in Brain Cells via Peroxisome Proliferator-activated Receptor $\hat{l}\pm$. Journal of Biological Chemistry, 2012, 287, 38922-38935.	1.6	40